Autonomix Medical, Inc. (AMIX)
NASDAQ: AMIX · Real-Time Price · USD
1.625
-0.045 (-2.69%)
At close: May 30, 2025, 4:00 PM
1.730
+0.105 (6.46%)
After-hours: May 30, 2025, 7:17 PM EDT
Autonomix Medical Employees
As of March 31, 2024, Autonomix Medical had 8 total employees, including 5 full-time and 3 part-time employees. The number of employees increased by 4 or 100.00% compared to the previous year.
Employees
8
Change (1Y)
4
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$1,426,250
Market Cap
4.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 8 | 4 | 100.00% |
| Mar 31, 2023 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AMIX News
- 16 days ago - Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology - GlobeNewsWire
- 17 days ago - Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event - GlobeNewsWire
- 18 days ago - Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market - GlobeNewsWire
- 26 days ago - Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain - GlobeNewsWire
- 4 weeks ago - Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - GlobeNewsWire
- 4 weeks ago - Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - GlobeNewsWire
- 5 weeks ago - Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR - GlobeNewsWire
- 6 weeks ago - Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire